Shaperon (XKRX:378800) Pre-Tax Income : ₩-15,890.71 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Shaperon Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Shaperon's pretax income for the three months ended in Sep. 2024 was ₩-2,919.72 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was ₩-15,890.71 Mil. Shaperon's pretax margin was %.

During the past 5 years, Shaperon's highest Pretax Margin was -534.14%. The lowest was -17416.77%. And the median was -4553.22%.

Shaperon Pre-Tax Income Historical Data

The historical data trend for Shaperon's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shaperon Pre-Tax Income Chart

Shaperon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

-13,238.15

-26,654.99

-23,806.03

-10,682.79

-12,387.56

Shaperon Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial							-2,360.47	-4,427.23	-4,837.03	-3,706.74	-2,919.72

Competitive Comparison of Shaperon's Pre-Tax Income

For the Biotechnology subindustry, Shaperon's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shaperon's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shaperon's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Shaperon's Pre-Tax Income falls into.

Shaperon Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Shaperon's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-13228.301	+	0	+	-36.185	+	910.13	+	-33.202000000001
	=	-12,387.56

Shaperon's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3085.076	+	0	+	-12.864	+	165.746	+	12.473
	=	-2,919.72

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-15,890.71 Mil.

Shaperon (XKRX:378800) Pre-Tax Income Explanation

Shaperon's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2919.721	/	0
	=	%

During the past 5 years, Shaperon's highest Pretax Margin was -534.14%. The lowest was -17416.77%. And the median was -4553.22%.

Shaperon Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Shaperon's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Shaperon Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shaperon Inc (XKRX:378800) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gangnam Ace Tower G9, Suie 218 & 606, 174-10 Jagok-ro, Gangnam-gu, Seoul, KOR, 06373

Website

http://www.shaperon.com

Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.

Shaperon Headlines

No Headlines